Physician profile
Alan Siqueiros
NPI 1861637597
$6,652.81
in general payments reported to CMS, 2019-2025
41 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $176 · 2021: $939 · 2022: $733 · 2023: $898 · 2024: $1,201 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,457.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,351.03 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $927.39 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.86 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $613.14 | 2019-2025 | Opsumit, Uptravi |
| Abbvie INC. | $346.15 | 2022-2025 | Avycaz |
| Genzyme Corporation | $345.27 | 2019-2025 | |
| Insmed, INC. | $269.16 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $267.13 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $263.87 | 2019-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $168.83 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $141.34 | 2019-2021 | |
| Intuitive Surgical, INC. | $130.80 | 2025 | |
| Grifols USA, LLC | $130.29 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $102.93 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $78.99 | 2019-2024 | Dupixent |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Siqueiros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.